SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment ...

On the call with me are Franz-Werner Haas, the Chief Executive Officer of CureVac; Klaus Edvardsen, our Chief Development Officer; and Pierre Kemula, Chief Financial Officer of CureVac. Please note ...

GSK announced Thursday morning that it signed an in-license agreement with LimmaTech Biologics to further develop and commercialize a vaccine candidate for shigella. The deal enables LimmaTech to work ...

BERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce ...

Franz-Werner Haas -- Chief Executive Officer And then certainly, on the IP field, if there are certain licenses to be needed, then certainly, we'll deal with the situation as well as we, of course, ...

Coronavirus vaccine maker CureVac has said it hopes its coronavirus shot will receive European approval in the second quarter. CureVac's CEO Franz-Werner Haas told CNBC Thursday that the vaccine maker ...

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih and I’m the Vice President of Corporate Communications and Investor Relations at CureVac. Please let ...